Triple-agent regimen improves survival
December 2019

BOTHELL, Wash.—Seattle Genetics Inc. recently shared top-line results from its HER2CLIMB trial of tucatinib in combination with trastuzumab and capecitabine vs. trastuzumab and capecitabine alone in patients with locally advanced unresectable or metastatic HER2-positive breast cancer. The combination of the three drugs reduced the risk of disease progression or death by 46 percent, meeting the primary endpoint of progression-free survival, as well as improving overall survival by 34 percent. In the tucatinib arm, patients whose cancer had metastasized to the brain saw a 52-percent reduction in the risk of disease progression or death. The combination regimen was generally well tolerated and presented a manageable safety profile.

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.